Specific lysis of melanoma cells by receptor grafted T cells is enhanced by anti-idiotypic monoclonal antibodies directed to the scFv domain of the receptor

Journal of Investigative Dermatology

Volumn 112, Issue 5, 1999, Pages 744-750

  Reinhold, Uwe ^a   Liu, Lide ^a   Lüdtke Handjery, Hans Christian ^a   Heuser, Claudia ^a   Hombach, Andreas ^a   Wang, Xinhui ^a,b   Tilgen, Wolfgang ^a   Ferrone, Soldano ^a,b   Abken, Hinrich ^a  

^a SAARLAND UNIVERSITY   (Germany)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Anti idiotypic monoclonal antibody; Cellular targeting; Chimeric T cell receptor

Indexed keywords

FC RECEPTOR; MELANOMA ANTIGEN; MONOCLONAL ANTIBODY;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CELL TRANSPLANTATION; CYTOLYSIS; CYTOPATHOGENIC EFFECT; HUMAN; IMMUNOPATHOGENESIS; MALIGNANT TRANSFORMATION; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SKIN CARCINOGENESIS; T LYMPHOCYTE ACTIVATION; TARGET CELL;

EID: 0032955712     PISSN: 0022202X     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1523-1747.1999.00586.x     Document Type: Article

References (37)

1. Abken H, Hombach A, Reinhold U, Ferrone S: Can combined T-cell-and antibody-based immunotherapy outsmart tumor cells? Immunol Today 19:2-5, 1998
2. Boon T: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365, 1994
3. Boon T, Cerottini JC, Van den Eynde B, van der Bruggen P, Van Pel A: Tumor antigens recognized by T lymphocytes. Annu Rev Immunol 12:337-365, 1994
4. Brodsky FM, Lem L, Bresnahan PA: Antigen processing and presentation. Tissue Antigens 47:464-471, 1996
5. Caruthers MH, Barone AD, Beaucage SL, et al: Chemical synthesis of deoxyoligonucleotides by the phosphoramidite method. Methods Enzymol 154:287-313, 1987
6. Chen ZJ, Yang H, Kageshita T, Ferrone S: Human high-molecular-weight melanoma-associated antigen mimicry by mouse antiidiotypic monoclonal antibody TK7-371. Cancer Res 51:4790-4797, 1991
7. Eshhar Z, Waks T, Gross G, Schindler DG: Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or ζ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci USA 90:720-724, 1993
8. Ferrone S, Marincola FM: Loss of HLA class I antigens by melanoma cells: molecular mechanisms, functional significance and clinical relevance. Immunol Today 16:487-494, 1995
9. Ferrone S, Temponi M, Gargiulo D, Scassellati GA, Cavaliere R, Natali PG: Selection and utilization of monoclonal antibody defined melanoma associated antigens of immunoscintigraphy in patients with melanoma. In: S.C. Srivastava (ed.), Radiolabeled Monoclonal Antibodies for Imaging and Therapy, Plenum Press, New York and London, 1988
10. Giacomini P, Ng AK, Kantor RRS, Natali PG Ferrone S: Double determinant immunoassay to measure a human high-molecular-weight melanoma-associated antigen. Cancer Res 43:3586-3590, 1983
11. Gross G, Eshhar Z: Endowing T cells with antibody specificity using chimeric T cell receptors. FASEB J 6:3370-3378, 1992
12. Gross G, Waks T, Eshhar Z: Expression of immunoglobulin-T cell receptor chimeric molecules as functional receptors with antibody-type specificity. Proc Natl Acad Sci USA 86:10024-10028, 1989
13. Hekele A, Dall P, Moritz D: Growth retardation of tumors by adoptive transfer of cytotoxic T lymphocytes reprogrammed by CD44v6-specific scHv: Zeta-chimera. Int J Cancer 68:232-238, 1996
14. + gastrointestinal tumor cells by a chimeric receptor with antibody-like specificity. Gastroenterology 113:1163-1170, 1997
15. Hombach A, Heuser C, Sircar R, Tillmann T, Diehl V, Pohl C, Abken H: An anti-CD30 chimeric receptor that mediates CD3-zeta independent T-cell activation against Hodgkin's lymphoma cells in presence of soluble GD30. Cancer Res 58:1116-1119, 1998a
16. Hombach A, Koch D, Sircar R, et al: Chimeric receptor that selectively targets membrane bound carcinoembryonic antigen (mCEA) in presence of soluble CEA. Gene Ther in press, 1998b
17. Hwu P, Shafer GE, Treisman J, et al: Lysis of ovarian cancer cells by human lymphocytes redirected with a chimeric gene composed of an antibody variable region and the Fc receptor γ chain. J Exp Med 178:361-366, 1993
18. Hwu P, Shafer GE, Treisman J, et al: Cytotoxic T lymphocytes with a grafted recognition specificity for ERBB2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318-4322, 1994
19. Hwu P, Yang JC, Cowherd R, Treisman J, Shafer GE, Eshhar Z, Rosenberg SA: In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes. Cancer Res 55:3369-3373, 1995
20. Kaufmann Y, Berke G, Eshhar Z: Cytotoxic T lymphocyte hybridomas that mediate specific tumor-cell lysis in vitro. Proc Natl Acad Sci USA 78:2502-2506, 1981
21. Koh HK: Cutaneous melanoma. N Engl J Med 325:171-182, 1991
22. Kusama M, Kageshita T, Chen ZJ, Ferrone S: Characterization of syngeneic antiidiotypic monoclonal antibodies to murine anti-human high molecular weight melanoma-associated antigen monoclonal antibodies. J Immunol 143:3844-3852, 1989
23. Laemmli UK: Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 227:680-685, 1970
24. McMichael A: Cytotoxic T lymphocytes and immune surveillance. Cancer Surv 13:5-21, 1992
25. Mittelman A, Chen ZJ, Kageshita T, et al: Active specific immunotherapy in patients with melanoma: a clinical trial with mouse antiidiotypic monoclonal antibodies elicited with syngeneic anti-high-molecular-weight-melanoma-associated antigen monoclonal antibodies. J Clin Invest 86:2136-2144, 1990
26. Moritz D, Wels W, Mattern J, Groner B: Cytotoxic T lymphocytes with a grafted recognition specificity for ErbB2-expressing tumor cells. Proc Natl Acad Sci USA 91:4318-4322, 1994
27. Perosa F, Kageshita T, Ono R, Ferrone S: Serological methods to detect anti idiotypic antibodies. Methods Enzymol 178:74-90, 1989
28. Rosenberg S: Development of cancer immunotherapies based on identification of the genes encoding cancer regression antigens. J Natl Cancer Inst 88:1635-1644, 1996
29. Sanger F, Nicklen S, Coulson A: DNA sequencing with chain terminating inhibitors. Proc Natl Acad Sci USA 74:5463-5467, 1977
30. Seliger B, Maeurer MJ, Ferrone S: TAP off-tumors on. Immunol Today 18:292 299, 1997
31. Spitler LE, Del Rio M, Khentigan A, et al: Therapy of patients with malignant melanoma using a monoclonal antimelanoma antibody-ricin A chain immunotoxin. Cancer Res 47:1717-1723, 1987
32. Stancovski I, Schindler DG, Waks T, Yarden Y, Sela M, Eshhar Z: Targeting of T lymphocytes to Ncu/HER2-expressing cells using chimeric single chain Fv receptors. J Immunol 151:6577-6582, 1993
33. Temponi M, Kageshita T, Perosa F, Ono R, Okada H, Ferrone S: Purification of murine IgG monoclonal antobodies by precipitation with caprylic acid: Comparison with other methods of purification. Hybridoma 8:85-95, 1989
34. Temponi M, Gold AM, Ferrone S: Binding parameters and idiotypic profile of the whole immunoglobulin and Fab' fragments of murine monoclonal antibody to distinct determinants of the human high molecular weight-melanoma associated antigen. Cancer Res 52:2497-2503, 1992
35. Weijtens MEM, Willemsen RA, Valerio D, Stam K, Bolhuis RLH: Single chain Ig/ γ gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity. J Immunol 157:836-843, 1996
36. Wilson BS, Imai K, Natali PG, Ferrone S: Distribution and molecular characterization of a cell-surface and a cytoplasmic antigen detectable in human melanoma cells with monoclonal antibodies. Int J Cancer 28:293-300, 1981
37. Wirthmüller U, Kurosaki T, Murakami MS, Ravetch JV: Signal transduction by Fc gamma RIII (CD16) is mediated through the gamma chain. J Exp Med 175:1381-1390, 1992